Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B
The experimentally established mechanism targets of Lanicemine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.77 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.77 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.77 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.77 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.77 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.77 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.77 |
| ▸ | PTPRA | P18433 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 2/20 | 0.44 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | KDM6B | O15054 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | KDM5C | P41229 | 1/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lanicemine SCHEMBL8779512 | 1.00 | GRIN2D (0.77) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Lanicemine SCHEMBL1650286 | 0.87 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Lanicemine SCHEMBL1422817 | 0.87 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Lanicemine SCHEMBL29379976 | 0.87 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Lanicemine SCHEMBL30415652 | 0.87 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Lanicemine SCHEMBL13557819 | 0.87 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Lanicemine SCHEMBL13517622 | 0.86 | GRIN2D (0.96) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Lanicemine SCHEMBL18094971 | 0.86 | GRIN2D (0.96) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Lanicemine SCHEMBL31444739 | 0.86 | GRIN2D (0.96) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Lanicemine SCHEMBL6021910 | 0.86 | GRIN2D (0.96) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0691958-B1 | (S)-ALPHA-PHENYL-2-PYRIDINEETHANAMINE BENZOATE AND ITS USE AS A MEDICAMENT | ASTRA AB (SE) | 1997-08-13 | — | — | EP | claimed |
| EP-0691958-A1 | (S)-ALPHA-PHENYL-2-PYRIDINEETHANAMINE BENZOATE AND ITS USE AS A MEDICAMENT | ASTRA AB (SE) | 1996-01-17 | — | — | EP | claimed |
| EP-0648745-A1 | Arylalkylamine having anticonvulsant and neuroprotective properties | Astra Aktiebolag (SE) | 1995-04-19 | — | — | EP | claimed |
| WO-1994022832-A1 | (S)-ALPHA-PHENYL-2-PYRIDINEETHANAMINE BENZOATE AND ITS USE AS A MEDICAMENT | ASTRA AKTIEBOLAG (SE) | 1994-10-13 | — | — | WO | claimed |
| EP-0691958-B1 | (S)-ALPHA-PHENYL-2-PYRIDINEETHANAMINE BENZOATE AND ITS USE AS A MEDICAMENT | ASTRA AB (SE) | 1997-08-13 | — | — | EP | disclosed |
| EP-0691958-A1 | (S)-ALPHA-PHENYL-2-PYRIDINEETHANAMINE BENZOATE AND ITS USE AS A MEDICAMENT | ASTRA AB (SE) | 1996-01-17 | — | — | EP | disclosed |
| WO-1994022832-A1 | (S)-ALPHA-PHENYL-2-PYRIDINEETHANAMINE BENZOATE AND ITS USE AS A MEDICAMENT | ASTRA AKTIEBOLAG (SE) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022832-A1 | (S)-ALPHA-PHENYL-2-PYRIDINEETHANAMINE BENZOATE AND ITS USE AS A MEDICAMENT | ASTRA AKTIEBOLAG (SE) | 1994-10-13 | — | — | WO | disclosed |